Wolfe Research Upgrades Vera Therapeutics (NASDAQ:VERA) to “Outperform”

Vera Therapeutics (NASDAQ:VERA) was upgraded by equities research analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating in a research report issued on Wednesday, MarketBeat.com reports. The firm presently has a $88.00 price objective on the stock. Wolfe Research’s target price points to a potential upside of 113.75% from the company’s current price.

VERA has been the topic of several other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a research report on Wednesday, November 26th. HC Wainwright raised their target price on shares of Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a report on Monday, March 2nd. The Goldman Sachs Group lifted their target price on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Bank of America upped their price target on shares of Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a report on Friday, December 19th. Finally, Wedbush increased their price target on shares of Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $81.45.

Vera Therapeutics Stock Performance

Shares of VERA stock opened at $41.17 on Wednesday. The stock has a fifty day moving average price of $43.98 and a 200 day moving average price of $36.62. The company has a debt-to-equity ratio of 0.12, a quick ratio of 13.64 and a current ratio of 13.64. The stock has a market cap of $2.88 billion, a PE ratio of -8.83 and a beta of 1.17. Vera Therapeutics has a 1 year low of $18.53 and a 1 year high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Thursday, February 26th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same quarter in the prior year, the business earned ($0.72) earnings per share. Sell-side analysts forecast that Vera Therapeutics will post -2.89 earnings per share for the current fiscal year.

Insider Activity at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 16,925 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $710,511.50. Following the sale, the chief executive officer owned 257,163 shares in the company, valued at $10,795,702.74. This trade represents a 6.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Joseph R. Young sold 3,117 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $130,851.66. Following the completion of the transaction, the senior vice president owned 64,722 shares of the company’s stock, valued at $2,717,029.56. The trade was a 4.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 33,490 shares of company stock worth $1,405,910. Company insiders own 16.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC lifted its holdings in shares of Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after acquiring an additional 236 shares during the period. Los Angeles Capital Management LLC purchased a new stake in Vera Therapeutics in the fourth quarter valued at approximately $46,000. Quantbot Technologies LP acquired a new position in Vera Therapeutics during the second quarter worth approximately $51,000. Aster Capital Management DIFC Ltd purchased a new position in Vera Therapeutics during the fourth quarter worth approximately $71,000. Finally, Virtus Investment Advisers LLC raised its stake in Vera Therapeutics by 14.8% during the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after purchasing an additional 539 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.